PTGS2 and neoplasm: Given the advantage of urinary samples, which enable repeated real-time assessment and do not require consideration of tumour heterogeneity in biomarker expression, PGE-MUM could be promising for evaluating the activity of the COX-2 pathway and reflecting the exact biological features of tumours.